Adult Dosing
General dosage
- 0.1-0.2 mg/kg PO daily for 3 to 6 weeks, as required
- Reduce dose if full course of radiation therapy or other myelosuppressive therapy is planned within 4 weeks
- Maintenance: 0.03-0.1 mg/kg (2-4 mg) PO daily
Chronic lymphocytic leukemia and other lymphomas
- Daily dose regimen: 0.1 mg/kg PO daily for 3-6 weeks
- Biweekly regimen (single daily dose q2 weeks): Initial 0.4 mg/kg, increased by 0.1 mg/kg q2 weeks until response or myelosuppression; up to 130 mg doses have been given
- Monthly regimen (single daily dose q4 weeks): Initial 0.4 mg/kg, increased by 0.2 mg/kg q4 weeks until response or myelosuppression; up to 1.5-2 mg/kg have been given
- Average duration: 3-12 mo, restart if relapse
Note: Many regimens have been recommended, individualize dose according to response of each patient. Prednisolone is required in cases of bone marrow suppression
Hodgkin's disease
- 0.2 mg/kg PO daily for 4-8 weeks
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
- Use only under the supervision of physician experienced in cancer chemotherapy
- Due to the carcinogenic properties, do not give for conditions other than those specified
- Acute leukemia has occurred in patients receiving concomitant chemotherapeutic agents and/or irradiation
- Chlorambucil may cause chromatid or chromosome damage in humans; permanent and reversible sterility observed in both sexes
- May cause fetal or neonatal harm; advise patients to avoid becoming pregnant; breast feed not recommended
- Dermatologic events of skin rash progressing to erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson Syndrome reported
- Do not give a full dosage before 4 wk after a full course of radiation therapy or chemotherapy because of the vulnerability of the bone marrow to damage under these conditions
- Monitor patient for signs and symptoms of bacterial, viral, or fungal infection
- Monitor CBC, platelet count, WBC with differential count qwk (WBC with differential 3-4 days after CBC during first 3-6 wks of treatment)
Cautions: Use cautiously in
- Myelosuppression
- Myelosuppressive agent use
- Recent XRT (do not use within 4 weeks)
- Hx of seizure disorder
- Head injury
- Infection
- Concomitant epileptogenic agent use
- Elderly population
- Long term use
Pregnancy Category:D
Breastfeeding: Most sources consider breastfeeding to be contraindicated with antineoplastic therapy.Breastfeeding is not recommended by mothers on chlorambucil.
Pricing data from www.DrugStore.com in U.S.A.
- Leukeran 2 MG TABS [Bottle] (PRASCO LABORATORIES)
30 mg = $134.99
90 mg = $374.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Leukeran 2 MG Oral Tablet
Ingredient(s): Chlorambucil
Imprint: GX;EG3;L
Color(s): Brown
Shape: Round
Size (mm): 7.00
Score: 1
Inactive Ingredient(s): silicon dioxide / hypromellose / anhydrous lactose / polyethylene glycol / cellulose, microcrystalline / ferric oxide red / stearic acid / titanium dioxide / ferric oxide yellow
Drug Label Author:
GlaxoSmithKline LLC
DEA Schedule:
Non-Scheduled
